Salix Pharmaceuticals (NASDAQ: SLXP) posted its quarterly earnings results on Thursday. The company reported $0.81 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.78 by $0.03. The company had revenue of $198.17 million for the quarter, compared to the consensus estimate of $199.85 million. During the same quarter last year, the company posted $1.18 earnings per share. Salix Pharmaceuticals’s revenue was up 27.7% compared to the same quarter last year. Salix Pharmaceuticals updated its FY13 guidance to approx $3.37 EPS.
Several analysts have also recently commented on the stock. Analysts at Janney Montgomery Scott initiated coverage on shares of Salix Pharmaceuticals in a research note to investors on Thursday, January 31st. They set a “buy” rating and a $55.00 price target on the stock. On the ratings front, analysts at RBC Capital initiated coverage on shares of Salix Pharmaceuticals in a research note to investors on Friday, January 11th. They set an “outperform” rating and a $53.00 price target on the stock. Finally, analysts at Zacks reiterated a “neutral” rating on shares of Salix Pharmaceuticals in a research note to investors on Friday, January 4th. They now have a $46.00 price target on the stock.
Salix Pharmaceuticals (SLXP) traded up 0.12% on Thursday, hitting $48.85. Salix Pharmaceuticals (SLXP) has a 52-week low of $37.52 and a 52-week high of $55.99. The stock’s 50-day moving average is currently $47.69. The company has a market cap of $2.874 billion and a price-to-earnings ratio of 37.85.
Salix Pharmaceuticals, Ltd. is a specialty pharmaceutical company engaged in acquiring, developing and commercializing prescription drugs and medical devices used in the treatment of a variety of gastrointestinal diseases, which are those affecting the digestive tract.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.
